keyword
MENU ▼
Read by QxMD icon Read
search

Guanfacine

keyword
https://www.readbyqxmd.com/read/29456930/review-of-the-evidence-for-the-management-of-co-morbid-tic-disorders-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#1
REVIEW
Michael O Ogundele, Hani F Ayyash
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children and adolescents, with prevalence ranging between 5% and 12% in the developed countries. Tic disorders (TD) are common co-morbidities in paediatric ADHD patients with or without pharmacotherapy treatment. There has been conflicting evidence of the role of psychostimulants in either precipitating or exacerbating TDs in ADHD patients. We carried out a literature review relating to the management of TDs in children and adolescents with ADHD through a comprehensive search of MEDLINE, EMBASE, CINAHL and Cochrane databases...
February 8, 2018: World Journal of Clinical Pediatrics
https://www.readbyqxmd.com/read/29442229/long-term-safety-and-efficacy-of-guanfacine-extended-release-in-children-and-adolescents-with-adhd
#2
Michael Huss, Bryan Dirks, Joan Gu, Brigitte Robertson, Jeffrey H Newcorn, J Antoni Ramos-Quiroga
Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Participants received dose-optimized GXR (1-7 mg/day) for up to 2 years. Of 215 enrolled participants, 214 were included in the safety population and 133 completed the study. Participants' mean age was 11.7 years and 73.8% were male. Overall, 177 participants (82.7%) experienced a treatment-emergent adverse event (TEAE)...
February 13, 2018: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/29436486/randomised-double-blind-placebo-controlled-crossover-study-of-single-dose-guanfacine-in-unilateral-neglect-following-stroke
#3
Edwin S Dalmaijer, Korina M S Li, Nikos Gorgoraptis, Alexander P Leff, David L Cohen, Andrew D Parton, Masud Husain, Paresh A Malhotra
OBJECTIVE: Unilateral neglect is a poststroke disorder that impacts negatively on functional outcome and lacks established, effective treatment. This multicomponent syndrome is characterised by a directional bias of attention away from contralesional space, together with impairments in several cognitive domains, including sustained attention and spatial working memory. This study aimed to test the effects of guanfacine, a noradrenergic alpha-2A agonist, on ameliorating aspects of neglect...
February 7, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29411149/pharmacological-treatment-of-attention-deficit-hyperactivity-disorder-during-pregnancy-and-lactation
#4
REVIEW
Asher Ornoy
INTRODUCTION: Attention deficit/hyperactivity disorder (ADHD) is a neurobehavioral problem found in 2-5% of adults. Stimulants and drugs that affect the dopaminergic, noradrenergic and/or serotonergic systems are effective treatment and are increasingly prescribed to women at child bearing age. It is consequently important that reliable information on the safety of these drugs in pregnancy is available so that appropriate therapeutic choices can be made. RESULTS: The data on stimulants (methylphenidate and amphetamines) are generally showing that there is no increase in the rate of major congenital anomalies...
February 6, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29398934/pharmacotherapy-of-emotional-and-behavioral-symptoms-associated-with-autism-spectrum-disorder-in-children-and-adolescents
#5
Ekaterina Stepanova, Susannah Dowling, Molly Phelps, Robert L Findling
Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD...
December 2017: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/29335879/current-approaches-and-new-developments-in-the-pharmacological-management-of-tourette-syndrome
#6
REVIEW
Julio Quezada, Keith A Coffman
Tourette syndrome (TS) is a neurodevelopmental disorder of unknown etiology characterized by spontaneous, involuntary movements and vocalizations called tics. Once thought to be rare, TS affects 0.3-1% of the population. Tics can cause physical discomfort, emotional distress, social difficulties, and can interfere with education and desired activities. The pharmacologic treatment of TS is particularly challenging, as currently the genetics, neurophysiology, and neuropathology of this disorder are still largely unknown...
January 15, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29313415/a-controlled-trial-of-extended-release-guanfacine-and-psychostimulants-on-executive-function-and-adhd
#7
Judy P M van Stralen
OBJECTIVE: To evaluate the effectiveness of guanfacine extended-release (GXR) versus placebo as adjunct therapy to usual care stimulant therapy in improving executive function in children aged 6 to 12 years diagnosed with ADHD. METHOD: In this single center, double-blind placebo-controlled crossover trial, subjects continued to take their psychostimulant and were randomly assigned at baseline to receive active treatment or placebo first. Efficacy measures included Behavioural Rating Inventory of Executive Function (BRIEF-P), ADHD Rating Scale IV (ADHD-RS IV), and Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) scales...
January 1, 2018: Journal of Attention Disorders
https://www.readbyqxmd.com/read/29298540/healthcare-utilization-and-costs-of-children-with-attention-deficit-hyperactivity-disorder-initiating-atomoxetine-versus-extended-release-guanfacine
#8
Cliff Molife, Virginia S Haynes, Allen Nyhuis, Douglas E Faries, Steve Gelwicks, Douglas K Kelsey, Carlos I Alatorre
OBJECTIVES: To compare 1-year direct healthcare costs and utilization among children and adolescents initiating non-stimulant medications atomoxetine (ATX) or extended-release guanfacine (GXR). METHODS: In this retrospective, observational cohort study, children and adolescents ages 6-17 years with ADHD who had ≥1 prescription claim for ATX or GXR between 12/31/2009-1/1/2011 were identified in the MarketScan Commercial or Multi-State Medicaid claims databases...
January 3, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29290742/off-label-prescribing-trends-for-adhd-medications-in-very-young-children
#9
Shannon G Panther, Alice M Knotts, Tamara Odom-Maryon, Kenneth Daratha, Teri Woo, Tracy A Klein
OBJECTIVE: This study examines off-label medication prescribing use and trends in children on Medicaid with ADHD with particular focus on the very young (under age 6 years). METHODS: This was an observational cohort study and retrospective analysis of ADHD medication prescriptions from Oregon Medicaid records (N = 83,190) in 2012. Manufacturer prescribing information was used to determine off-label designation. Children ages 3 to 18 years at the time of prescription who had continuous Medicaid enrollment of at least 10 months during the index year of 2012 were included in the sample frame...
November 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29282674/correction-to-development-of-guanfacine-extended-release-dosing-strategies-in-children-and-adolescents-with-adhd-using-a-physiologically-based-pharmacokinetic-model-to-predict-drug-drug-interactions-with-moderate-cyp3a4-inhibitors-or-inducers
#10
Aiqun Li, Karen Yeo, Devin Welty, Haojing Rong
The article "Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a PhysiologicallyBased Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers", written by Aiqun Li, Karen Yeo, Devin Welty, Haojing Rong, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 02nd November, 2017 without open access.
December 28, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29237331/autism-spectrum-disorder-consensus-guidelines-on-assessment-treatment-and-research-from-the-british-association-for-psychopharmacology
#11
Oliver D Howes, Maria Rogdaki, James L Findon, Robert H Wichers, Tony Charman, Bryan H King, Eva Loth, Gráinne M McAlonan, James T McCracken, Jeremy R Parr, Carol Povey, Paramala Santosh, Simon Wallace, Emily Simonoff, Declan G Murphy
An expert review of the aetiology, assessment, and treatment of autism spectrum disorder, and recommendations for diagnosis, management and service provision was coordinated by the British Association for Psychopharmacology, and evidence graded. The aetiology of autism spectrum disorder involves genetic and environmental contributions, and implicates a number of brain systems, in particular the gamma-aminobutyric acid, serotonergic and glutamatergic systems. The presentation of autism spectrum disorder varies widely and co-occurring health problems (in particular epilepsy, sleep disorders, anxiety, depression, attention deficit/hyperactivity disorder and irritability) are common...
January 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29201635/successful-use-of-guanfacine-in-a-patient-with-chronic-refractory-cough-a-case-report
#12
Gregory W Kirschen, Howard Kirschen, Edward Gabalski, Jonathan M Waxner, Agnes Wohl
Chronic idiopathic cough is a common and often frustrating complaint for patients as well as providers. When common etiologies of cough are ruled out and/or do not respond to usual treatments, neurogenic cough should be considered as a diagnosis of exclusion. Here, we report on a 58-year-old woman with an 8-year history of chronic, treatment-refractory cough of unknown etiology that we diagnosed as neurogenic cough and successfully treated with guanfacine monotherapy, with rapid and durable improvement in symptoms...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/29186993/medication-use-in-adults-with-attention-deficit-hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states
#13
Zhou Zhou, Zheng-Yi Zhou, Sneha S Kelkar, Vanja Sikirica, Jipan Xie, Regina Grebla
OBJECTIVE: To examine real-world prescription medication usage among commercially-insured adults with attention deficit/hyperactivity disorder (ADHD) in the US. METHODS: Adults with ADHD who received ≥1 ADHD medication during 2013 were identified from a large US claims database. Combination therapy was defined as an overlap of ≥30 days between the index (first treatment ≥30 days in 2013) and another medication(s). Patients were classified into six groups: long-acting (LA) monotherapy, short-acting (SA) monotherapy, LA + LA, SA + SA, LA + SA, and >2 therapies...
December 8, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29180967/efficacy-and-tolerability-of-different-interventions-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#14
Ruiling Luan, Zhiling Mu, Fang Yue, Shaoying He
Background: Our study is an analysis of multiple publications involving assessing the comparable efficacy and tolerability of six interventions, which are lisdexamfetamine dimesylate (LDX), atomoxetine (ATX), methylphenidate (MPH), clonidine hydrochloride (CLON), guanfacine extended release (GXR), and bupropion, for young patients (6-18 years old) suffering from attention deficit hyperactivity disorder (ADHD). Methods: A conventional meta-analysis (MA) was performed to give direct comparisons and a network meta-analysis (NMA) was used to show the combination of direct and indirect evidence...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29129665/intravasation-of-sw620-colon-cancer-cell-spheroids-through-the-blood-endothelial-barrier-is-inhibited-by-clinical-drugs-and-flavonoids-in-vitro
#15
Silvio Holzner, Stefan Brenner, Atanas Georgiev Atanasov, Daniel Senfter, Serena Stadler, Chi Huu Nguyen, Adryan Fristiohady, Daniela Milovanovic, Nicole Huttary, Sigurd Krieger, Zsuzsanna Bago-Horvath, Oliver de Wever, Ioannis Tentes, Ali Özmen, Walter Jäger, Helmut Dolznig, Verena Maria Dirsch, Robert Michael Mader, Liselotte Krenn, Georg Krupitza
Mechanisms how colorectal cancer (CRC) cells penetrate blood micro-vessel endothelia and metastasise is poorly understood. To study blood endothelial cell (BEC) barrier breaching by CRC emboli, an in vitro assay measuring BEC-free areas underneath SW620 cell spheroids, so called "circular chemorepellent induced defects" (CCIDs, appearing in consequence of endothelial retraction), was adapted and supported by Western blotting, EIA-, EROD- and luciferase reporter assays. Inhibition of ALOX12 or NF-κB in SW620 cells or BECs, respectively, caused attenuation of CCIDs...
November 10, 2017: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29098603/development-of-guanfacine-extended-release-dosing-strategies-in-children-and-adolescents-with-adhd-using-a-physiologically-based-pharmacokinetic-model-to-predict-drug-drug-interactions-with-moderate-cyp3a4-inhibitors-or-inducers
#16
Aiqun Li, Karen Yeo, Devin Welty, Haojing Rong
BACKGROUND: Guanfacine extended-release (GXR) is an orally administered, non-stimulant treatment for children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and is primarily metabolized by the 3A4 isozyme of cytochrome P450 (CYP3A4). The results of clinical pharmacokinetic (PK) studies indicate that guanfacine is sensitive to drug-drug interactions (DDIs) perpetrated by strong inhibitors and inducers of CYP3A4. OBJECTIVE: The aim was to provide guidance on the possible requirement for GXR dose adjustment in children and adolescents with ADHD by predicting DDIs following co-administration with moderate CYP3A4 inhibitors and inducers...
November 2, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28984477/pediatric-pharmacoepidemiology-safety-and-effectiveness-of-medicines-for-adhd
#17
REVIEW
Antonio Clavenna, Maurizio Bonati
Attention-deficit hyperactivity disorder (ADHD) is a common neurobehavioral disorder in children and adolescents that comprises core symptoms of developmentally inappropriate levels of inattention and/or hyperactivity and impulsivity. Stimulant (methylphenidate, amphetamines) and non stimulant (atomoxetine, clonidine and guanfacine) are the treatment usually prescribed for ADHD. Area covered: This review covers the safety of ADHD medications in children and adolescents. MEDLINE, EMBASE and PsycINFO databases were searched with the aim to retrieve prospective studies that monitored the incidence of adverse events (AEs) in children receiving drug therapy for ADHD...
December 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28944773/the-effect-of-treatment-with-guanfacine-an-alpha2-adrenergic-agonist-on-dopaminergic-tone-in-tobacco-smokers-an-11-c-flb457-pet-study
#18
Christine M Sandiego, David Matuskey, Meaghan Lavery, Erin McGovern, Yiyun Huang, Nabeel Nabulsi, Jim Ropchan, Marina R Picciotto, Evan D Morris, Sherry A McKee, Kelly P Cosgrove
Guanfacine, a noradrenergic alpha2a agonist, reduced tobacco smoking in a 4-week trial and in animal models has been shown to reduce cortical dopamine release, which is critically involved in the reinforcing effect of tobacco smoking. We measured amphetamine-induced extrastriatal dopamine release before and after treatment with guanfacine with [(11)C]FLB457, a dopamine D2/D3 receptor radiotracer, and positron emission tomography (PET). Sixteen tobacco smokers had one set of [(11)C]FLB457 PET scans on the same day, one before and one at 2...
September 25, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28893219/a-case-of-a-four-year-old-child-adopted-at-eight-months-with-unusual-mood-patterns-and-significant-polypharmacy
#19
Magdalena Romanowicz, Alastair J McKean, Jennifer Vande Voort
BACKGROUND: Long-term effects of neglect in early life are still widely unknown. Diversity of outcomes can be explained by differences in genetic risk, epigenetics, prenatal factors, exposure to stress and/or substances, and parent-child interactions. Very common sub-threshold presentations of children with history of early trauma are challenging not only to diagnose but also in treatment. CASE PRESENTATION: A Caucasian 4-year-old, adopted at 8 months, male patient with early history of neglect presented to pediatrician with symptoms of behavioral dyscontrol, emotional dysregulation, anxiety, hyperactivity and inattention, obsessions with food, and attachment issues...
September 11, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28836895/correlations-between-clinical-trial-outcomes-based-on-symptoms-functional-impairments-and-quality-of-life-in-children-and-adolescents-with-adhd
#20
David R Coghill, Alain Joseph, Vanja Sikirica, Mark Kosinski, Caleb Bliss, Michael Huss
OBJECTIVE: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD. METHOD: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference)...
August 1, 2017: Journal of Attention Disorders
keyword
keyword
7575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"